Abstract
Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are a major global public health concern. Presently, Escherichia coli with CTX-Ms are the most common species associated with global ESBLs; CTX-M-15 is the most frequent CTX-M worldwide and is followed by CTX-M-14, which is often found in South-East Asia. Recent surveillance studies showed that CTX-M-27 is emerging in certain parts of the world especially in Japan and Europe. The population structure of ESBL-producing E. coli is dominated globally by an high-risk clone named ST131. Escherichia coli ST131 belongs to three clades (A, B, and C) and three different subclades (C1, C1-M27, and C2). Clade C1-M27 is associated with blaCTX-M-27, and C2 with blaCTX-M-15. Recent whole genome sequencing studies have shown that clade C has evolved from clade B in a stepwise fashion, resulting in one of the most influential global antimicrobial resistance clones that has emerged during the 2000’s. Other important E. coli clones that have been detected among ESBL producers include ST405, ST38, ST648, ST410, and ST1193. The INCREMENT project has shown that ertapenem is as effective as other carbapenems for treating serious infections due to ESBL-producing Enterobacteriaceae. The results of the MERINO open-label randomized controlled study has provided clear evidence that piperacillin-tazobactam should be avoided for targeted therapy of blood-stream infections due to ESBL-producing E. coli and K. pneumoniae, regardless of the patient population, source of infection, bacterial species, and susceptibility result of piperacillin-tazobactam. Research is still warranted to define the optimal therapy of less severe infections due to ESBL-producing Enterobactericeae.
Similar content being viewed by others
References
Seale AC, Gordon NC, Islam J, Peacock SJ, Scott JAG. AMR Surveillance in low and middle-income settings: a roadmap for participation in the Global Antimicrobial Surveillance System (GLASS). Wellcome Open Res. 2017;2:92. https://doi.org/10.12688/wellcomeopenres.12527.1.
Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36(1):53–9. https://doi.org/10.1086/345476.
Marchaim D, Gottesman T, Schwartz O, Korem M, Maor Y, Rahav G, et al. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 2010;54(12):5099–104. https://doi.org/10.1128/AAC.00565-10.
Bush K, Bradford PA. Beta-lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med. 2016. https://doi.org/10.1101/cshperspect.a025247.
Bonomo RA. Beta-lactamases: a focus on current challenges. Cold Spring Harb Perspect Med. 2017. https://doi.org/10.1101/cshperspect.a025239.
Drawz SM, Bonomo RA. Three decades of beta-lactamase inhibitors. Clin Microbiol Rev. 2010;23(1):160–201. https://doi.org/10.1128/CMR.00037-09.
Bush K. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci. 2013;1277:84–90. https://doi.org/10.1111/nyas.12023.
Ambler RP, Coulson AF, Frere JM, Ghuysen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A beta-lactamases. Biochem J. 1991;276(Pt 1):269–70.
Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969–76. https://doi.org/10.1128/AAC.01009-09.
Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–66. https://doi.org/10.1016/S1473-3099(08)70041-0.
Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother. 2005;56(1):52–9. https://doi.org/10.1093/jac/dki166.
Pitout JD. Extraintestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Front Microbiol. 2012;3:9. https://doi.org/10.3389/fmicb.2012.00009.
World Health Organization. Antimicrobial resistance: global report on surveillance. 2014. http://www.who.int/drugresistance/documents/surveillancereport/en/. Accessed Jun 2014.
Lowe M, Kock MM, Coetzee J, Hoosien E, Peirano G, Strydom KA, et al. Klebsiella pneumoniae ST307 with blaOXA-181, South Africa, 2014–2016. Emerg Infect Dis. 2019;25(4):739–47. https://doi.org/10.3201/eid2504.181482.
Pitout JD, Nordmann P, Poirel L. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother. 2015;59(10):5873–84. https://doi.org/10.1128/AAC.01019-15.
Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, et al. Beta-lactamase database (BLDB): structure and function. J Enzyme Inhib Med Chem. 2017;32(1):917–9. https://doi.org/10.1080/14756366.2017.1344235.
Poirel L, Gniadkowski M, Nordmann P. Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. J Antimicrob Chemother. 2002;50(6):1031–4.
Karim A, Poirel L, Nagarajan S, Nordmann P. Plasmid-mediated extended-spectrum beta-lactamase (CTX-M-3 like) from India and gene association with insertion sequence ISEcp1. FEMS Microbiol Lett. 2001;201(2):237–41. https://doi.org/10.1111/j.1574-6968.2001.tb10762.x.
Pai H, Choi EH, Lee HJ, Hong JY, Jacoby GA. Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol. 2001;39(10):3747–9. https://doi.org/10.1128/JCM.39.10.3747-3749.2001.
Bevan ER, Jones AM, Hawkey PM. Global epidemiology of CTX-M beta-lactamases: temporal and geographical shifts in genotype. J Antimicrob Chemother. 2017;72(8):2145–55. https://doi.org/10.1093/jac/dkx146.
Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313–33. https://doi.org/10.2165/11533040-000000000-00000.
Ladner JT, Grubaugh ND, Pybus OG, Andersen KG. Precision epidemiology for infectious disease control. Nat Med. 2019;25(2):206–11. https://doi.org/10.1038/s41591-019-0345-2.
Baker S, Thomson N, Weill FX, Holt KE. Genomic insights into the emergence and spread of antimicrobial-resistant bacterial pathogens. Science. 2018;360(6390):733–8. https://doi.org/10.1126/science.aar3777.
Mathers AJ, Peirano G, Pitout JD. The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015;28(3):565–91. https://doi.org/10.1128/CMR.00116-14.
Baquero F, Tedim AP, Coque TM. Antibiotic resistance shaping multi-level population biology of bacteria. Front Microbiol. 2013;4:15. https://doi.org/10.3389/fmicb.2013.00015.
Partridge SR, Kwong SM, Firth N, Jensen SO. Mobile genetic elements associated with antimicrobial resistance. Clin Microbiol Rev. 2018. https://doi.org/10.1128/cmr.00088-17.
Siguier P, Gourbeyre E, Chandler M. Bacterial insertion sequences: their genomic impact and diversity. FEMS Microbiol Rev. 2014;38(5):865–91. https://doi.org/10.1111/1574-6976.12067.
Poirel L, Lartigue MF, Decousser JW, Nordmann P. ISEcp1B-mediated transposition of blaCTX-M in Escherichia coli. Antimicrob Agents Chemother. 2005;49(1):447–50. https://doi.org/10.1128/AAC.49.1.447-450.2005.
Carattoli A. Plasmids and the spread of resistance. Int J Med Microbiol. 2013;303(6–7):298–304. https://doi.org/10.1016/j.ijmm.2013.02.001.
Zhao WH, Hu ZQ. Epidemiology and genetics of CTX-M extended-spectrum beta-lactamases in Gram-negative bacteria. Crit Rev Microbiol. 2013;39(1):79–101. https://doi.org/10.3109/1040841X.2012.691460.
Lartigue MF, Poirel L, Aubert D, Nordmann P. In vitro analysis of ISEcp1B-mediated mobilization of naturally occurring beta-lactamase gene blaCTX-M of Kluyvera ascorbata. Antimicrob Agents Chemother. 2006;50(4):1282–6. https://doi.org/10.1128/AAC.50.4.1282-1286.2006.
Poirel L, Decousser JW, Nordmann P. Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene. Antimicrob Agents Chemother. 2003;47(9):2938–45. https://doi.org/10.1128/aac.47.9.2938-2945.2003.
Canton R, Gonzalez-Alba JM, Galan JC. CTX-M enzymes: origin and diffusion. Front Microbiol. 2012;3:110. https://doi.org/10.3389/fmicb.2012.00110.
Carattoli A. Resistance plasmid families in Enterobacteriaceae. Antimicrob Agents Chemother. 2009;53(6):2227–38. https://doi.org/10.1128/AAC.01707-08.
Shin J, Choi MJ, Ko KS. Replicon sequence typing of IncF plasmids and the genetic environments of blaCTX-M-15 indicate multiple acquisitions of blaCTX-M-15 in Escherichia coli and Klebsiella pneumoniae isolates from South Korea. J Antimicrob Chemother. 2012;67(8):1853–7. https://doi.org/10.1093/jac/dks143.
Zong Z. Complete sequence of pJIE186-2, a plasmid carrying multiple virulence factors from a sequence type 131 Escherichia coli O25 strain. Antimicrob Agents Chemother. 2013;57(1):597–600. https://doi.org/10.1128/AAC.01081-12.
Stoesser N, Sheppard AE, Pankhurst L, De Maio N, Moore CE, Sebra R, et al. Evolutionary history of the global emergence of the Escherichia coli epidemic clone ST131. MBio. 2016;7(2):e02162. https://doi.org/10.1128/mBio.02162-15.
Nicolas-Chanoine MH, Bertrand X, Madec JY. Escherichia coli ST131, an intriguing clonal group. Clin Microbiol Rev. 2014;27(3):543–74. https://doi.org/10.1128/CMR.00125-13.
Pitout JD, DeVinney R. Escherichia coli ST131: a multidrug-resistant clone primed for global domination. F1000Res. 2017. https://doi.org/10.12688/f1000research.10609.1.
Peirano G, van der Bij AK, Gregson DB, Pitout JD. Molecular epidemiology over an 11-year period (2000–2010) of extended-spectrum beta-lactamase-producing Escherichia coli causing bacteremia in a centralized Canadian region. J Clin Microbiol. 2012;50(2):294–9. https://doi.org/10.1128/JCM.06025-11.
Petty NK, Ben Zakour NL, Stanton-Cook M, Skippington E, Totsika M, Forde BM, et al. Global dissemination of a multidrug resistant Escherichia coli clone. Proc Natl Acad Sci USA. 2014;111(15):5694–9. https://doi.org/10.1073/pnas.1322678111.
Price LB, Johnson JR, Aziz M, Clabots C, Johnston B, Tchesnokova V, et al. The epidemic of extended-spectrum-beta-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio. 2013;4(6):e00377. https://doi.org/10.1128/mBio.00377-13.
Peirano G, Pitout JD. Fluoroquinolone-resistant Escherichia coli sequence type 131 isolates causing bloodstream infections in a Canadian region with a centralized laboratory system: rapid emergence of the H30-Rx sublineage. Antimicrob Agents Chemother. 2014;58(5):2699–703. https://doi.org/10.1128/AAC.00119-14.
Ben Zakour NL, Alsheikh-Hussain AS, Ashcroft MM, Khanh Nhu NT, Roberts LW, Stanton-Cook M, et al. Sequential acquisition of virulence and fluoroquinolone resistance has shaped the evolution of Escherichia coli ST131. MBio. 2016;7(2):e00347. https://doi.org/10.1128/mBio.00347-16.
Johnson TJ, Danzeisen JD, Youmans B, Case K, Llop K, Munoz-Aguayo J, et al. Separate F-type plasmids have shaped the evolution of the H30 subclone of Escherichia coli sequence type 131. mSphere. 2016. https://doi.org/10.1128/msphere.00121-16.
Matsumura Y, Pitout JD, Gomi R, Matsuda T, Noguchi T, Yamamoto M, et al. Global Escherichia coli sequence type 131 clade with blaCTX-M-27 gene. Emerg Infect Dis. 2016;22(11):1900–7. https://doi.org/10.3201/eid2211.160519.
Matsumura Y, Johnson JR, Yamamoto M, Nagao M, Tanaka M, Takakura S, et al. CTX-M-27- and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. J Antimicrob Chemother. 2015;70(6):1639–49. https://doi.org/10.1093/jac/dkv017.
Ghosh H, Doijad S, Falgenhauer L, Fritzenwanker M, Imirzalioglu C, Chakraborty T. blaCTX-M-27-encoding Escherichia coli sequence type 131 lineage C1-M27 clone in clinical isolates, Germany. Emerg Infect Dis. 2017;23(10):1754–6. https://doi.org/10.3201/eid2310.170938.
Birgy A, Bidet P, Levy C, Sobral E, Cohen R, Bonacorsi S. CTX-M-27-producing Escherichia coli of sequence type 131 and clade C1-M27, France. Emerg Infect Dis. 2017;23(5):885. https://doi.org/10.3201/eid2305.161865.
Merino I, Hernandez-Garcia M, Turrientes MC, Perez-Viso B, Lopez-Fresnena N, Diaz-Agero C, et al. Emergence of ESBL-producing Escherichia coli ST131-C1-M27 clade colonizing patients in Europe. J Antimicrob Chemother. 2018;73(11):2973–80. https://doi.org/10.1093/jac/dky296.
Schaufler K, Semmler T, Wieler LH, Trott DJ, Pitout J, Peirano G, et al. Genomic and functional analysis of emerging virulent and multi-drug resistant E. coli lineage ST648. Antimicrob Agents Chemother. 2019;78:89. https://doi.org/10.1128/aac.00243-19.
Karfunkel D, Carmeli Y, Chmelnitsky I, Kotlovsky T, Navon-Venezia S. The emergence and dissemination of CTX-M-producing Escherichia coli sequence type 131 causing community-onset bacteremia in Israel. Eur J Clin Microbiol Infect Dis. 2013;32(4):513–21. https://doi.org/10.1007/s10096-012-1765-9.
Manges AR, Mende K, Murray CK, Johnston BD, Sokurenko EV, Tchesnokova V, et al. Clonal distribution and associated characteristics of Escherichia coli clinical and surveillance isolates from a military medical center. Diagn Microbiol Infect Dis. 2017;87(4):382–5. https://doi.org/10.1016/j.diagmicrobio.2017.01.007.
Matsumura Y, Noguchi T, Tanaka M, Kanahashi T, Yamamoto M, Nagao M, et al. Population structure of Japanese extraintestinal pathogenic Escherichia coli and its relationship with antimicrobial resistance. J Antimicrob Chemother. 2017;72(4):1040–9. https://doi.org/10.1093/jac/dkw530.
Wang S, Zhao SY, Xiao SZ, Gu FF, Liu QZ, Tang J, et al. Antimicrobial resistance and molecular epidemiology of Escherichia coli causing bloodstream infections in three hospitals in Shanghai, China. PLoS One. 2016;11(1):e0147740. https://doi.org/10.1371/journal.pone.0147740.
Bubpamala J, Khuntayaporn P, Thirapanmethee K, Montakantikul P, Santanirand P, Chomnawang MT. Phenotypic and genotypic characterizations of extended-spectrum beta-lactamase-producing Escherichia coli in Thailand. Infect Drug Resist. 2018;11:2151–7. https://doi.org/10.2147/IDR.S174506.
Shaik S, Ranjan A, Tiwari SK, Hussain A, Nandanwar N, Kumar N, et al. Comparative genomic analysis of globally dominant ST131 clone with other epidemiologically successful extraintestinal pathogenic Escherichia coli (ExPEC) lineages. MBio. 2017. https://doi.org/10.1128/mbio.01596-17.
Valenza G, Werner M, Eisenberger D, Nickel S, Lehner-Reindl V, Holler C, et al. First report of the new emerging global clone ST1193 among clinical isolates of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli from Germany. J Glob Antimicrob Resist. 2019. https://doi.org/10.1016/j.jgar.2019.01.014.
Manges AR, Geum HM, Guo A, Edens TJ, Fibke CD, Pitout JDD. Global extraintestinal pathogenic Escherichia coli (ExPEC) lineages. Clin Microbiol Rev. 2019. https://doi.org/10.1128/cmr.00135-18.
Peirano G, Pitout JD. Molecular epidemiology of Escherichia coli producing CTX-M beta-lactamases: the worldwide emergence of clone ST131 O25:H4. Int J Antimicrob Agents. 2010;35(4):316–21. https://doi.org/10.1016/j.ijantimicag.2009.11.003.
Talaminos A, Lopez-Cerero L, Calvillo J, Pascual A, Roa LM, Rodriguez-Bano J. Modelling the epidemiology of Escherichia coli ST131 and the impact of interventions on the community and healthcare centres. Epidemiol Infect. 2016;144(9):1974–82. https://doi.org/10.1017/S0950268816000030.
Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing Enterobacteriaceae. Clin Microbiol Rev. 2018. https://doi.org/10.1128/cmr.00079-17.
Harris PN, Tambyah PA, Paterson DL. Beta-lactam and beta-lactamase inhibitor combinations in the treatment of extended-spectrum beta-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015;15(4):475–85. https://doi.org/10.1016/S1473-3099(14)70950-8.
Muhammed M, Flokas ME, Detsis M, Alevizakos M, Mylonakis E. Comparison between carbapenems and beta-lactam/beta-lactamase inhibitors in the treatment for bloodstream infections caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a systematic review and meta-analysis. Open Forum Infect Dis. 2017. https://doi.org/10.1093/ofid/ofx099.
Palacios-Baena ZR, Gutierrez-Gutierrez B, De Cueto M, Viale P, Venditti M, Hernandez-Torres A, et al. Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2017;72(3):906–13. https://doi.org/10.1093/jac/dkw513.
Harris PNA, Pezzani MD, Gutierrez-Gutierrez B, Viale P, Hsueh PR, Ruiz-Garbajosa P, et al. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. Int J Antimicrob Agents. 2017;50(5):664–72. https://doi.org/10.1016/j.ijantimicag.2017.08.005.
Scheuerman O, Schechner V, Carmeli Y, Gutierrez-Gutierrez B, Calbo E, Almirante B, et al. Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol. 2018;39(6):660–7. https://doi.org/10.1017/ice.2018.63.
Gutierrez-Gutierrez B, Perez-Galera S, Salamanca E, de Cueto M, Calbo E, Almirante B, et al. A multinational, preregistered cohort study of beta-lactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(7):4159–69. https://doi.org/10.1128/AAC.00365-16.
Palacios-Baena ZR, Gutierrez-Gutierrez B, Calbo E, Almirante B, Viale P, Oliver A, et al. Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: results from the INCREMENT cohort. Clin Infect Dis. 2017;65(10):1615–23. https://doi.org/10.1093/cid/cix606.
Gutierrez-Gutierrez B, Bonomo RA, Carmeli Y, Paterson DL, Almirante B, Martinez-Martinez L, et al. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. J Antimicrob Chemother. 2016;71(6):1672–80. https://doi.org/10.1093/jac/dkv502.
Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin–tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA. 2018;320(10):984–94. https://doi.org/10.1001/jama.2018.12163.
Hayden MK, Won SY. Carbapenem-sparing therapy for extended-spectrum beta-lactamase-producing E. coli and Klebsiella pneumoniae bloodstream infection: the search continues. JAMA. 2018;320(10):979–81. https://doi.org/10.1001/jama.2018.12565.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This work was supported in part by research Grants from the Calgary Laboratory Services (#10015169 and #10017905).
Conflict of interest
Gisele Peirano and Johann D.D. Pitout have no conflicts of interest that are directly relevant to the content of this article.
Rights and permissions
About this article
Cite this article
Peirano, G., Pitout, J.D.D. Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Update on Molecular Epidemiology and Treatment Options. Drugs 79, 1529–1541 (2019). https://doi.org/10.1007/s40265-019-01180-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-019-01180-3